Pharmaceuticals

Multiple Sclerosis Treatment Market Expected to Reach $33.02 Billion by 2030 at a CAGR of 4.7%

March 23, 2026March 23, 2026 by Marketing Posting

The Business Research Company’s 2026 market reports include new capabilities such as market attractiveness scoring and analysis, total addressable market analysis, company scoring matrix, interactive excel data dashboard, improved supply chain analysis, upcoming startups in the market, and overview of key products, aimed at improving the depth, usability, and strategic value of the insights delivered.

What Market Value Is Anticipated For The Multiple Sclerosis Treatment Market Over The Period 2026–2030?

The multiple sclerosis treatment market has experienced robust growth in recent years. This market is projected to increase from $26.13 billion in 2025 to $27.44 billion in 2026, at a compound annual growth rate (CAGR) of 5.0%. The historical growth can be attributed to factors such as advancements in autoimmune disease research, the development of injectable MS therapies, the expansion of neurology clinics, the availability of hospital-based treatment, and progress in biologics development.

The multiple sclerosis treatment market is projected to experience consistent expansion over the upcoming years. This market is set to reach $33.02 billion by 2030, exhibiting a compound annual growth rate (CAGR) of 4.7%. Key factors driving this growth during the forecast period include the increasing adoption of oral therapies, the rise of home-based MS care, advancements in long-term disease management, the development of advanced imaging diagnostics, and the emergence of personalized immunotherapy. Significant trends anticipated in the forecast period involve the broadening availability of disease-modifying therapies, the increased use of oral MS medications, a greater emphasis on early diagnosis, the growing application of monoclonal antibodies, and the implementation of personalized treatment strategies.

Download the Free Sample Report to Explore Key Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=24612&type=smp

Which Economic Or Industry Drivers Are Impacting The Multiple Sclerosis Treatment Market?

The increasing occurrence of neurological disorders is anticipated to fuel the expansion of the multiple sclerosis treatment market moving forward. These medical conditions impact the brain, spinal cord, and nerves throughout the body, leading to difficulties with movement, communication, behavior, or fundamental bodily functions. The rise in neurological disorders is linked to an aging population, as longer lifespans elevate the risk of age-related issues such as Alzheimer’s. Multiple sclerosis treatment assists in managing neurological disorders by targeting the immune system to lessen inflammation, prevent nerve damage, and ease symptoms, thereby improving the quality of life for patients. For instance, in October 2023, the World Federation of Neurology, a UK-based association of national neurological societies, reported that more than 40% of the global population currently suffers from some type of neurological condition, and this prevalence is expected to nearly double by 2050. Thus, the escalating prevalence of neurological disorders is propelling the growth of the multiple sclerosis treatment market.

How Is The Multiple Sclerosis Treatment Market Divided Into Its Major Segments?

The multiple sclerosis treatment market covered in this report is segmented –

1) By Treatment Type: Immunomodulators, Corticosteroids, Symptomatic Treatments, Monoclonal Antibodies, Oral Therapies

2) By DiseaseType: Clinically Isolated Syndrome, Relapse-Remitting Multiple Sclerosis, Primary Progressive Multiple Sclerosis, Secondary Progressive Multiple Sclerosis

3) By Route Of Administration: Oral, Injectable, Intravenous

4) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies

5) By End-Users: Hospitals, Specialty Clinics, Homecare, Other End-Users

Subsegments:

1) By Immunomodulators: Interferon Beta-1A, Interferon Beta-1B, Glatiramer Acetate

2) By Corticosteroids: Methylprednisolone, Prednisone, Dexamethasone

3) By Symptomatic Treatments: Muscle Relaxants, Antidepressants, Anticonvulsants, Bladder Dysfunction Drugs

4) By Monoclonal Antibodies: Natalizumab, Ocrelizumab, Alemtuzumab, Ofatumumab

5) By Oral Therapies: Fingolimod, Dimethyl Fumarate, Teriflunomide, Cladribine, Siponimod

How Are Trends Transforming The Multiple Sclerosis Treatment Market Landscape?

Key players in the multiple sclerosis treatment market are innovating advanced solutions, such as monoclonal antibody medications, to uplift treatment effectiveness and better patient outcomes. Monoclonal antibody drugs are laboratory-crafted molecules engineered to pinpoint specific antigens, and in the context of multiple sclerosis, they aid by lessening inflammation and hindering immune cells from assaulting nerve fibers, thereby regulating the disease’s advancement. For example, in February 2024, Roche Pharma India, a pharmaceutical entity situated in India, unveiled Ocrevus (Ocrelizumab) for addressing multiple sclerosis (MS). This particular medication targets CD20-positive B cells, which helps in mitigating inflammation and nerve damage in MS. It stands as the inaugural approved therapy for both the relapsing and primary progressive manifestations of MS, substantially reducing relapse frequencies and delaying the progression of disability, offering the benefit of twice-yearly infusions.

Who Are The Prominent Organizations Shaping The Multiple Sclerosis Treatment Market?

Major companies operating in the multiple sclerosis treatment market are Biogen Inc., F. Hoffmann-La Roche Ltd, Novartis AG, Bayer AG, Teva Pharmaceutical Industries Ltd, Sanofi Genzyme, Merck KGaA, Bristol Myers Squibb, AbbVie Inc., Johnson & Johnson (Janssen), TG Therapeutics Inc., Acorda Therapeutics Inc., Takeda Pharmaceutical Company Ltd, Mitsubishi Tanabe Pharma Corporation, Chugai Pharmaceutical Co. Ltd., Pfizer Inc., Almirall S.A., Otsuka Pharmaceutical Co. Ltd., Apitope International NV, BrainStorm Cell Therapeutics Inc., Roche Diagnostics, InnoCare Pharma, NervGen Pharma Corp., Receptos Inc., Biogen Idec International GmbH, MedDay Pharmaceuticals SA, Genentech Inc., Roche Holding AG

Read the full multiple sclerosis treatment market report here:

https://www.thebusinessresearchcompany.com/report/multiple-sclerosis-treatment-global-market-report

What Are The Top-Performing Regions Within The Multiple Sclerosis Treatment Market?

North America was the largest region in the multiple sclerosis treatment market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the multiple sclerosis treatment market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request A Tailored Multiple Sclerosis Treatment Market Research Report For Competitive Advantage:

https://www.thebusinessresearchcompany.com/customise?id=24612&type=smp

Browse Through More Reports Similar to the Global Multiple Sclerosis Treatment Market 2026, By The Business Research Company

Rare Neurological Disease Treatment Market Report 2026

https://www.thebusinessresearchcompany.com/report/rare-neurological-disease-treatment-global-market-report

Neuralgia Treatment Market Report 2026

https://www.thebusinessresearchcompany.com/report/neuralgia-treatment-global-market-report

Progressive Multifocal Leukoencephalopathy Treatment Market Report 2026

https://www.thebusinessresearchcompany.com/report/progressive-multifocal-leukoencephalopathy-treatment-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795